Semantic Scholar uses AI to extract papers important to this topic.
The REDUC clinical study Part B investigated Vacc-4x/rhuGM-CSF therapeutic vaccination prior to HIV latency reversal… Expand BACKGROUND
Immune priming before reversal of latency might be a component of a functional HIV cure. To assess this concept, we… Expand Methods In this single-arm, phase 1B/2A trial, we recruited adults treated at the Department of Infectious Diseases, Aarhus… Expand BACKGROUND
Present combination antiretroviral therapy (cART) alone does not cure HIV infection and requires lifelong drug… Expand Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal… Expand Vacc-4x is being developed by Bionor Immuno AS as a therapeutic vaccine to be used in conjunction with antiretroviral therapies… Expand Delayed-type hypersensitivity (DTH) testing represents a simple in vivo method for monitoring cellular immune responses. In a… Expand We have previously shown that HIV p24-like peptides (Vacc-4x) via activation of skin dendritic cells induced immune responses in… Expand Objective: The Vacc-4x immunotherapy candidate is composed of four modified peptides corresponding to conserved domains of the… Expand Highly active antiretroviral therapy (HAART) can effectively suppress HIV-1 replication but, as soon as the drugs are withdrawn… Expand